{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T04:12:16Z","timestamp":1760933536459,"version":"build-2065373602"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.pmr.2018.04.008","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T00:49:38Z","timestamp":1527900578000},"page":"501-517","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pharmacologic Treatment Tools"],"prefix":"10.1016","volume":"29","author":[{"given":"Peter","family":"Riedel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Marino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/PL00005604","article-title":"Baclofen: reduction of presynaptic calcium influx in the cat spinal cord in\u00a0vivo","volume":"113","author":"Curtis","year":"1997","journal-title":"Exp Brain Res"},{"issue":"4","key":"10.1016\/j.pmr.2018.04.008_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0301-0082(95)00012-K","article-title":"A\u00a0physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system","volume":"46","author":"Misgeld","year":"1995","journal-title":"Prog Neurobiol"},{"issue":"14","key":"10.1016\/j.pmr.2018.04.008_bib3","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1073\/pnas.85.14.5330","article-title":"Activation of type B gamma-aminobutyric acid receptors in the intact mammalian spinal cord mimics the effects of reduced presynaptic Ca2+ influx","volume":"85","author":"Lev-Tov","year":"1988","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"10","key":"10.1016\/j.pmr.2018.04.008_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0028-3908(82)90109-5","article-title":"The effects of baclofen on gamma motoneurones supplying gastrocnemius muscle in the rabbit","volume":"21","author":"Harrison","year":"1982","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.pmr.2018.04.008_bib5","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0021-5198(19)52603-8","article-title":"Effects of chlorpromazine, imipramine and baclofen on the spinal polysynaptic reflex in acute, chronic and 6-hydroxydopamine-treated spinal rats","volume":"32","author":"Ito","year":"1982","journal-title":"Jpn J Pharmacol"},{"issue":"11","key":"10.1016\/j.pmr.2018.04.008_bib6","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0028-3908(82)90165-4","article-title":"Pharmacological studies on the prolonged depressant effects of baclofen on lumbar dorsal horn units in the cat","volume":"21","author":"Henry","year":"1982","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pmr.2018.04.008_bib7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1212\/WNL.26.5.441","article-title":"An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study","volume":"26","author":"Duncan","year":"1976","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pmr.2018.04.008_bib8","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1212\/WNL.28.11.1094","article-title":"Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study","volume":"28","author":"Feldman","year":"1978","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.pmr.2018.04.008_bib9","first-page":"278","article-title":"Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy","volume":"4","author":"Roussan","year":"1985","journal-title":"Pharmatherapeutica"},{"issue":"11","key":"10.1016\/j.pmr.2018.04.008_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2165\/00002018-200427110-00004","article-title":"A\u00a0benefit-risk assessment of baclofen in severe spinal spasticity","volume":"27","author":"Dario","year":"2004","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.pmr.2018.04.008_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/BF00613463","article-title":"Baclofen in the elderly stroke patient its side-effects and pharmacokinetics","volume":"29","author":"Hulme","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.pmr.2018.04.008_bib12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/archneur.1981.00510090082011","article-title":"Complications of baclofen withdrawal","volume":"38","author":"Terrence","year":"1981","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.1981.tb05284.x","article-title":"GABA-benzodiazepine-barbiturate receptor interactions","volume":"37","author":"Olsen","year":"1981","journal-title":"J\u00a0Neurochem"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0304-3940(82)90365-2","article-title":"Diazepam enhancement of low affinity GABA binding to rat brain membranes","volume":"29","author":"Skerritt","year":"1982","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.pmr.2018.04.008_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/BF00504702","article-title":"The effect of diazepam on spinal cord activities: possible sites and mechanisms of action","volume":"284","author":"Polc","year":"1974","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib16","first-page":"19","article-title":"A\u00a0double blind, cross-over trial of Valium in the treatment of spasticity","volume":"10","author":"Corbett","year":"1972","journal-title":"Paraplegia"},{"key":"10.1016\/j.pmr.2018.04.008_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/jama.1965.03080100015003","article-title":"Diazepam in incapacitated cerebral-palsied children","volume":"191","author":"Marsh","year":"1965","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","author":"Riss","year":"2008","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2165\/00003495-198632020-00003","article-title":"Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity","volume":"32","author":"Ward","year":"1986","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0006-8993(83)90631-5","article-title":"Action of dantrolene sodium on single motor units of cat muscle in\u00a0vivo","volume":"261","author":"Jami","year":"1983","journal-title":"Brain Res"},{"key":"10.1016\/j.pmr.2018.04.008_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1113\/jphysiol.1981.sp013851","article-title":"The effect of dantrolene sodium on intrafusal muscle fibres in the rat soleus muscle","volume":"318","author":"Leslie","year":"1981","journal-title":"J\u00a0Physiol"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1185\/03007998409109576","article-title":"Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function","volume":"9","author":"Ketel","year":"1984","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00007611-197102000-00011","article-title":"The effects of dantrolene sodium on spasticity and motor performance in hemiplegia","volume":"64","author":"Chyatte","year":"1971","journal-title":"South Med J"},{"issue":"12","key":"10.1016\/j.pmr.2018.04.008_bib24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.23.12.1313","article-title":"The effect of dantrolene sodium on spasticity in multiple sclerosis","volume":"23","author":"Gelenberg","year":"1973","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00003495-197713010-00002","article-title":"Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity","volume":"13","author":"Pinder","year":"1977","journal-title":"Drugs"},{"issue":"4 Pt 1","key":"10.1016\/j.pmr.2018.04.008_bib26","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0016-5085(77)80141-8","article-title":"Dantrolene-associated hepatic injury. Incidence and character","volume":"72","author":"Utili","year":"1977","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1476-5381.1982.tb09242.x","article-title":"Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2, 1, 3-benzothiodazole (DS103\u2013282)","volume":"76","author":"Davies","year":"1982","journal-title":"Br J Pharmacol"},{"issue":"11 Suppl 9","key":"10.1016\/j.pmr.2018.04.008_bib28","first-page":"S6","article-title":"Tizanidine: neuropharmacology and mechanism of action","volume":"44","author":"Coward","year":"1994","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","article-title":"Tizanidine is mainly metabolized by cytochrome p450 1A2 in\u00a0vitro","volume":"57","author":"Granfors","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"11 Suppl 9","key":"10.1016\/j.pmr.2018.04.008_bib30","first-page":"S44","article-title":"Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group","volume":"44","author":"Nance","year":"1994","journal-title":"Neurology"},{"issue":"11 Suppl 9","key":"10.1016\/j.pmr.2018.04.008_bib31","first-page":"S70","article-title":"A\u00a0double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis","volume":"44","author":"United Kingdom Tizanidine Trial Group","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF01061374","article-title":"Tizanidine in the treatment of spasticity","volume":"23","author":"Newman","year":"1982","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.pmr.2018.04.008_bib33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jnnp.43.12.1132","article-title":"Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity","volume":"43","author":"Hassan","year":"1980","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.pmr.2018.04.008_bib34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1185\/03007998809111122","article-title":"A\u00a0multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia","volume":"10","author":"Bes","year":"1988","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.pmr.2018.04.008_bib35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1185\/03007998909110141","article-title":"A\u00a0double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions","volume":"11","author":"Medici","year":"1989","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib36","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","article-title":"Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders","volume":"53","author":"Wagstaff","year":"1997","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.pmr.2018.04.008_bib37","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/0736-4679(95)02019-5","article-title":"Five-year multicenter retrospective review of cyclobenzaprine toxicity","volume":"13","author":"Spiller","year":"1995","journal-title":"J\u00a0Emerg Med"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1586\/ecp.09.5","article-title":"Cyclobenzaprine: a new look at an old pharmacological agent","volume":"2","author":"Cimolai","year":"2009","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.pmr.2018.04.008_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/jnnp.35.5.599","article-title":"Assessment of cyclobenzaprine in the treatment of spasticity","volume":"35","author":"Ashby","year":"1972","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"9","key":"10.1016\/j.pmr.2018.04.008_bib40","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1073\/pnas.0708930105","article-title":"Pharmacological disruption of calcium channel trafficking by the \u03b12\u03b4 ligand gabapentin","volume":"105","author":"Hendrich","year":"2008","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0920-1211(93)90078-L","article-title":"Gabapentin anticonvulsant action in rats: disequilibrium with peak drug concentrations in plasma and brain microdialysate","volume":"16","author":"Welty","year":"1993","journal-title":"Epilepsy Res"},{"issue":"6 Suppl 5","key":"10.1016\/j.pmr.2018.04.008_bib42","first-page":"S17","article-title":"Clinical pharmacokinetics of gabapentin","volume":"44","author":"McLean","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sc.2010.67","article-title":"Gabapentin for spasticity and autonomic dysreflexia after severe spinal cord injury","volume":"49","author":"Rabchevsky","year":"2011","journal-title":"Spinal Cord"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0003-9993(00)90135-7","article-title":"Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial","volume":"81","author":"Cutter","year":"2000","journal-title":"Arch Phys Med Rehabil"},{"issue":"10","key":"10.1016\/j.pmr.2018.04.008_bib45","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/sj.sc.3100481","article-title":"Gabapentin for the treatment of spasticity in patients with spinal cord injury","volume":"35","author":"Gruenthal","year":"1997","journal-title":"Spinal Cord"},{"issue":"Suppl 1","key":"10.1016\/j.pmr.2018.04.008_bib46","first-page":"S45","article-title":"Overview of the safety of newer antiepileptic drugs","volume":"38","author":"Shorvon","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.pmr.2018.04.008_bib47","series-title":"Marihuana: the first twelve thousand years","first-page":"182","author":"Abel","year":"1980"},{"key":"10.1016\/j.pmr.2018.04.008_bib48","unstructured":"Statement of Dr. William C. Woodward, legislative council, American Medical Association; 2017. Available at: http:\/\/www.druglibrary.org\/Schaffer\/hemp\/taxact\/woodward.htm. Accessed March 11, 2018."},{"key":"10.1016\/j.pmr.2018.04.008_bib49","unstructured":"DEA\/Drug Scheduling 2018. Available at: https:\/\/www.dea.gov\/druginfo\/ds.shtml. Accessed March 11, 2018."},{"key":"10.1016\/j.pmr.2018.04.008_bib50","unstructured":"State Medical Marijuana Laws. National Conference of State Legislatures. Available at: http:\/\/www.ncsl.org\/research\/health\/state-medical-marijuana-laws.aspx. Accessed November 3, 2017."},{"key":"10.1016\/j.pmr.2018.04.008_bib51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pneurobio.2017.10.007","article-title":"The endocannabinoid system and its therapeutic exploitation in multiple sclerosis: Clues for other neuroinflammatory diseases","volume":"160","author":"Chiurchi\u00f9","year":"2018","journal-title":"Prog Neurobiol"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib52","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and \u0394(9)-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"14","key":"10.1016\/j.pmr.2018.04.008_bib53","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1177\/1352458513485982","article-title":"Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors","volume":"19","author":"Pryce","year":"2013","journal-title":"Mult Scler"},{"year":"2006","series-title":"Product information: Marinol\u00ae, dronabinol oral capsules","author":"Solvay Pharmaceuticals","key":"10.1016\/j.pmr.2018.04.008_bib54"},{"year":"2006","series-title":"Product information: Cesamet\u2122, nabilone oral capsules","author":"Valeant Pharmaceuticals","key":"10.1016\/j.pmr.2018.04.008_bib55"},{"key":"10.1016\/j.pmr.2018.04.008_bib56","unstructured":"GW Pharma. Product information: Sativex\u00ae oromucosal spray summary of product characteristics, 2014. Available at: http:\/\/www.medicines.org.uk\/emc\/medicine\/23262. Accessed March 11, 2018."},{"issue":"8\u20139 Suppl","key":"10.1016\/j.pmr.2018.04.008_bib57","first-page":"413S","article-title":"Treatment of human spasticity with delta 9-tetrahydrocannabinol","volume":"21","author":"Petro","year":"1981","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.pmr.2018.04.008_bib58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00207458608985678","article-title":"Open label evaluation of cannabidiol in dystonic movement disorders","volume":"30","author":"Consroe","year":"1986","journal-title":"Int J Neurosci"},{"issue":"9395","key":"10.1016\/j.pmr.2018.04.008_bib59","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(03)14738-1","article-title":"Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial","volume":"362","author":"Zajicek","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pmr.2018.04.008_bib60","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1136\/jnnp.2005.070136","article-title":"Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12\u00a0months follow up","volume":"76","author":"Zajicek","year":"2005","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib61","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1468-1331.2006.01639.x","article-title":"Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis","volume":"14","author":"Collin","year":"2007","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.pmr.2018.04.008_bib62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1179\/016164109X12590518685660","article-title":"A\u00a0double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis","volume":"32","author":"Collin","year":"2010","journal-title":"Neurol Res"},{"issue":"9","key":"10.1016\/j.pmr.2018.04.008_bib63","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(\u00ae)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol"},{"issue":"5\u20136","key":"10.1016\/j.pmr.2018.04.008_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000357427","article-title":"Nabiximols (THC\/CBD oromucosal spray, Sativex\u00ae) in clinical practice\u2013results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity","volume":"71","author":"Flachenecker","year":"2014","journal-title":"Eur Neurol"},{"issue":"12","key":"10.1016\/j.pmr.2018.04.008_bib65","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1212\/WNL.0000000000000250","article-title":"Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology","volume":"82","author":"Yadav","year":"2014","journal-title":"Neurology"},{"issue":"17","key":"10.1016\/j.pmr.2018.04.008_bib66","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1212\/WNL.0000000000000363","article-title":"Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Koppel","year":"2014","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib67","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11910-018-0814-x","article-title":"The use of cannabis and cannabinoids in treating symptoms of multiple sclerosis: a systematic review of reviews","volume":"18","author":"Nielsen","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/cpt.721","article-title":"Cannabis smoking and cardiovascular health: it's complicated","volume":"102","author":"Piano","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure, and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pmr.2018.04.008_bib70","first-page":"131","article-title":"Botulinum toxin in the treatment of upper limb spasticity","volume":"vol. 11","author":"Brashear","year":"2011"},{"issue":"6442","key":"10.1016\/j.pmr.2018.04.008_bib71","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/365160a0","article-title":"Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25","volume":"365","author":"Blasi","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.pmr.2018.04.008_bib72","unstructured":"Botulinum toxin safety warnings updated and name changes issued. Available at: https:\/\/www.medscape.com\/viewarticle\/706934. Accessed December 16, 2017."},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/16501977-0303","article-title":"European consensus table on the use of botulinum toxin type A and adult spasticity","volume":"41","author":"Wissel","year":"2009","journal-title":"J\u00a0Rehabil Med"},{"issue":"19","key":"10.1016\/j.pmr.2018.04.008_bib74","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000311391.00944.c4","article-title":"Assessment: botulinum neurotoxin for the treatment of spasticity (and evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib75","doi-asserted-by":"crossref","first-page":"256","DOI":"10.23736\/S1973-9087.16.04329-X","article-title":"Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: systematic review with meta-analysis and trial sequential analysis","volume":"53","author":"Dong","year":"2017","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.pmr.2018.04.008_bib76","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type a free from complexing proteins; NT 201) in poststroke upper limb spasticity","volume":"43","author":"Kanovsky","year":"2011","journal-title":"J\u00a0Rehabil Med"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/0269905031000149498","article-title":"Functional outcome following botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury","volume":"18","author":"Fock","year":"2004","journal-title":"Brain Inj"},{"key":"10.1016\/j.pmr.2018.04.008_bib78","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.apmr.2003.10.015","article-title":"Dose-dependent response to intramuscular botulinum toxin type a for upper-limb spasticity in patients after a stroke","volume":"85","author":"Childers","year":"2004","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib79","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PHM.0000000000000208","article-title":"Systematic literature review of abobotulinumtoxinA in clinical trials for adult upper limb spasticity","volume":"94","author":"Dashtipour","year":"2015","journal-title":"Am J Phys Med Rehabil"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0000000000002468","article-title":"Systematic literature review of abobotulinumtoxinA in clinical trials for lower limb spasticity","volume":"95","author":"Dashtipour","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.pmr.2018.04.008_bib81","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp.61.3.265","article-title":"A\u00a0randomized, double blind, placebo-controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients","volume":"61","author":"Barbaud","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pmr.2018.04.008_bib82","first-page":"483","article-title":"Safety and efficacy of incobotulinum toxini type A (NT 201-Xeomin) for the treatment of post-stroke lower limb spasticity: a prospective open-label study","volume":"49","author":"Santomato","year":"2013","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.pmr.2018.04.008_bib83","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/apmr.2003.50070","article-title":"treatment with botulinum toxin type B for upper limb spasticity","volume":"84","author":"Brashear","year":"2003","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.pmr.2018.04.008_bib84","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.apmr.2014.03.016","article-title":"Botulinum toxin type B in the spastic arm: a randomized, double-blind, placebo-controlled, preliminary study","volume":"95","author":"Gracies","year":"2014","journal-title":"Arch Phys Med Rehabil"},{"issue":"22","key":"10.1016\/j.pmr.2018.04.008_bib85","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1001\/jama.2009.780","article-title":"FDA requires black box warnings on labeling for botulinum toxin products","volume":"301","author":"Kuehn","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pmr.2018.04.008_bib86","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1520\/JFS2004196","article-title":"Fatal case of BOTOX-related anaphylaxis?","volume":"50","author":"Li","year":"2005","journal-title":"J\u00a0Forensic Sci"},{"issue":"3","key":"10.1016\/j.pmr.2018.04.008_bib87","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":"Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases","volume":"53","author":"Cote","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1055\/s-2004-830902","article-title":"Pearls and pitfalls in the therapeutic use of botulinum toxin","volume":"24","author":"Smith","year":"2004","journal-title":"Semin Neurol"},{"issue":"4","key":"10.1016\/j.pmr.2018.04.008_bib89","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jbiomech.2007.11.016","article-title":"Botox produces functional weakness in non-injected muscles adjacent to the target muscle","volume":"41","author":"Yaraskavitch","year":"2008","journal-title":"J\u00a0Biomech"},{"issue":"4","key":"10.1016\/j.pmr.2018.04.008_bib90","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1212\/WNL.46.4.1158","article-title":"Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion","volume":"46","author":"Eleopra","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.pmr.2018.04.008_bib91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.pmrj.2014.09.021","article-title":"Botulinum toxin injection techniques for the management of adult spasticity","volume":"7","author":"Walker","year":"2015","journal-title":"PMR"},{"key":"10.1016\/j.pmr.2018.04.008_bib92","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/09638288.2013.791727","article-title":"Effectiveness of botulinum toxin injection with and without needle electromyographic guidance for the treatment of spasticity and hemiplegic patients: a randomized control trial","volume":"36","author":"Ploumis","year":"2014","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.pmr.2018.04.008_bib93","first-page":"800","article-title":"A\u00a0randomized controlled trial to compare to botulinum toxin injection techniques on the functional improvement of the leg of children with cerebral palsy","volume":"2009","author":"Xu","year":"2009","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.pmr.2018.04.008_bib94","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.rehab.2009.02.005","article-title":"evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance","volume":"52","author":"Py","year":"2009","journal-title":"Ann Phys Med Rehabil Med"},{"key":"10.1016\/j.pmr.2018.04.008_bib95","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.apmr.2007.10.022","article-title":"Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia","volume":"89","author":"Mayer","year":"2008","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.pmr.2018.04.008_bib96","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/0269215513497735","article-title":"Botulinum toxin injection into the forearm muscles for wrist and fingers spastic overactivity in adults with chronic stroke: a randomized controlled trial comparing 3 injection techniques","volume":"28","author":"Picelli","year":"2014","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.pmr.2018.04.008_bib97","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","volume":"120","author":"Naumann","year":"2013","journal-title":"J\u00a0Neural Transm"},{"issue":"2","key":"10.1016\/j.pmr.2018.04.008_bib98","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2165\/11599840-000000000-00000","article-title":"Clinical relevance of botulinum toxin immunogenicity","volume":"26","author":"Benecke","year":"2012","journal-title":"BioDrugs"},{"issue":"suppl","key":"10.1016\/j.pmr.2018.04.008_bib99","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1097\/01.PHM.0000141128.62598.81","article-title":"Botulinum toxin: dosing and dilution","volume":"83","author":"Francisco","year":"2004","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.pmr.2018.04.008_bib100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.toxicon.2017.09.007","article-title":"Patterns of botulinum toxin treatment for spasticity and bleeding complications in patients with thrombotic risk","volume":"138","author":"Phadke","year":"2017","journal-title":"Toxicon"},{"key":"10.1016\/j.pmr.2018.04.008_bib101","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.pmrj.2017.06.002","article-title":"Prevalence of bleeding complication following ultrasound guided botulinum toxin injection in patients on anticoagulation of antiplatelet therapy","volume":"9","author":"Lavallee","year":"2017","journal-title":"PMR"}],"container-title":["Physical Medicine and Rehabilitation Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965118307745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047965118307745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T03:41:26Z","timestamp":1760931686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047965118307745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1047965118307745"],"URL":"https:\/\/doi.org\/10.1016\/j.pmr.2018.04.008","relation":{},"ISSN":["1047-9651"],"issn-type":[{"type":"print","value":"1047-9651"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Treatment Tools","name":"articletitle","label":"Article Title"},{"value":"Physical Medicine and Rehabilitation Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pmr.2018.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}